The company applies its therapeutic expertise in RNAi to significant medical needs.

Its outlook for its outlook for key scientific, clinical, and business initiatives, Alnylam has RNAi 2010 which includes the company ‘s plan to significantly expand the scope of delivery solutions for RNAi therapeutics, four or more programs in clinical development established and to form four or more new major business collaborations, all by the end of 2010. Alnylam is a joint owner of Regulus Therapeutics LLC, a joint venture in the discovery, Development and commercialization of microRNA therapeutics focused. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit.. About Alnylam Pharmaceuticals – based Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi.

Atul Gawande, associate professor of health policy and management at HSPH and a surgeon at Brigham and Women’s Hospital, and co-principal investigator Jonathan Spector, research associate in the Health Policy and Management at HSPH and a neonatologist at Massachusetts General Hospital, which lead Better Birth clinical trial. The study will evaluate the effect of the WHO Safe checklist checklist program in hospitals in Uttar Pradesh, India..’We are pleased to put this important study going, ‘said William A. Columbia University Medical Center, national principal investigator for the Gore to encourage Clinical Study. ‘Key unit attribute including low crossroads profile, smooth tip transition and reliable vascular wall apposition of were evidences and has proven advantageous in a difficult event. ‘.

** EMPiRE: embolic Protection System to Reverse flow Study of the GORE flow reversal system into carotis stenting of of topics with high risk for carotid endarterectomy.